Track your progress
Download the HD Chorea Treatment Tracking Guide to record when
AUSTEDO XR is taken and note any questions for your healthcare provider.
Go about
your day
with reduced involuntary movements1
Once-daily AUSTEDO XR (deutetrabenazine) extended-release tablets contains the same active ingredient
as twice-daily AUSTEDO (deutetrabenazine) tablets. Data on this page is based on twice-daily dosing. 1
In a 12-week clinical study,
AUSTEDO significantly
reduced HD chorea1
People taking AUSTEDO saw more than
2x reduction in HD chorea vs placebo.*
*4.4-point improvement in people taking AUSTEDO vs 1.9 in people taking placebo based on Total Maximal Chorea (TMC) score. The TMC score is used to measure HD chorea movements in the face, mouth, trunk, both arms, and both legs.1,2
established safety results
~3 years3
This was an open-label study, which is a drug trial in which all participants are aware of the drug being tested.4
People reported improvement in HD chorea symptoms1,2
Both doctors and people with HD chorea on AUSTEDO rated symptoms as “very much improved” or “much improved” at 12 weeks with AUSTEDO.
†Treatment success is measured by perceived improvement in TMC score.
People reported improvement in their ability to perform daily activities like2,5:
- Climbing stairs
- Bending, kneeling, or stooping
- Lifting/carrying groceries
- Walking
- Dressing
- Bathing
- Moderate to vigorous activities
People taking AUSTEDO achieved greater improvement in the SF-36§ Physical Functioning Score at 12 weeks vs placebo.
See study details§SF-36=36-Item Short Form Health Survey assessing health-related quality of life.
AUSTEDO XR/AUSTEDO does not cure the cause of the involuntary movements and it does not
treat the other symptoms of HD, such as problems with thinking or emotions.1
See why Ray and Rhonda made the decision to treat HD chorea
When HD chorea threatened to disrupt Ray and Rhonda's retirement plans, they knew it was time to ask Ray's doctor about treatment options.
Now Playing:
Ray and Rhonda's Story
See why Ray and Rhonda made the decision to treat HD chorea.
Video Transcript:
Ray
I'm Ray. I’m 55.
Rhonda
My name is Rhonda, and I am Ray's wife.
Rhonda
Ray's dad had Huntington's disease. He wasn’t, wasn't able to walk. He ended up in a wheelchair. So that was kind of a really scary thought for me. I just assumed that our lives would be over very soon as we knew it.
Rhonda
So the first symptoms I noticed of his chorea was at night while he was sleeping, his arms would, you know, kind of start flailing and hitting and kind of it would just be like his whole body.
Ray
When I was driving to work one day, my hands started just shaking like this. It’s just weird you know, having your hands move and no, no explanation.
Rhonda
At that time. It was I was feeling a little bit desperate, like something needs to change. We can't do this anymore.
Rhonda
We made an appointment with the neurologist that week talking to her about how bad it had gotten, and she said, well, I have this drug that I would like for you to try.
Rhonda
Yeah, so his movements just became less and less as the doses increased. His sleeping now is very different. No more kicks, no more punches, no more flailing around in bed. We both noticed that small things that he would do with his hands became easier.
Ray
Yeah.
Rhonda
Buttoning his shirt, putting the leash on the dog's collar, tying his shoes. Those things became easier. So, yeah, it has far exceeded our expectations.
Rhonda
We're looking forward to taking a trip to Yellowstone. Hopefully taking our grandkids and doing some hiking. I don't know that we would have been able to continue hiking with his chorea had it continued on without the medication. I feel like that we're actually like living the way we've always wanted to live now. By going on vacations and being outdoors a lot more and having grandkids and yeah, I can't imagine life if he didn't have the medication.
Ray
It's really a deal maker for me. It just helps so much.
APPROVED USES
AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® (deutetrabenazine) tablets are prescription medicines that are used to treat:
the involuntary movements (chorea) of Huntington’s disease. AUSTEDO XR and AUSTEDO do not cure the cause of the involuntary movements, and it does not treat other symptoms of Huntington’s disease, such as problems with thinking or emotions.
movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
It is not known if AUSTEDO XR and AUSTEDO are safe and effective in children.
IMPORTANT SAFETY INFORMATION
AUSTEDO XR and AUSTEDO can cause serious side effects in people with Huntington’s disease, including: depression, suicidal thoughts, or suicidal actions. Do not start taking AUSTEDO XR or AUSTEDO if you are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings. This is especially important when AUSTEDO XR or AUSTEDO is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of suicide.
Individual results may vary.
Please see the Important Safety Information at the end of this video.
Start the conversation now
Whether you're ready to start medication or planning
ahead, talking to a healthcare provider (for example, your doctor or nurse practitioner) is an important step.
Are you a healthcare professional?
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
References:
1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.
2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
3. Frank S, Testa CM, Stamler D, et al; Huntington Study Group ARC-HD Investigators. Long-term efficacy and safety of deutetrabenazine for chorea in Huntington's disease: results from the ARC-HD open-label study. Poster presented at: 27th Annual Meeting of the Huntington Study Group (HSG); October 29-31, 2020.
4. Open-label. Merriam-Webster. Updated January 1, 2024. Accessed January 24, 2024. https://www.merriam-webster.com/dictionary/open-label#medicalDictionary
5. Burgess JC, Davis B, Fogarty E, et al. Caregiver Guide for Mid to Late Stage Huntington's Disease: For Long-Term Care Facilities and In-Home Care Agencies. Huntington's Disease Society of America; 2014. Accessed January 24, 2024. http://hdsa.org/wp-content/uploads/2015/04/CaregiverGuide_Mid_Late_StageHD.pdf